ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 20124186

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Wick W and 12 others. J Clin Oncol, 2010. Cited by 406 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. Papers, record 20124186. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20124186

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
PubMed
Journal
J Clin Oncol
PubMed
Year
2010
PubMed
Publication types
Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
406
iCite
Relative citation ratio, by iCite
10.1
iCite
Revised in PubMed
2022-03-30
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wick WWolfgang
2Puduvalli VKVinay K
3Chamberlain MCMarc C
4van den Bent MJMartin J
5Carpentier AFAntoine F
6Cher LMLawrence M
7Mason WWarren
8Weller MMichael
9Hong SShengyan
10Musib LLuna

1 to 10 of 13Source PubMed

See all 13 authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Brain NeoplasmsMajor topic
GlioblastomaMajor topic
IndolesMajor topic
LomustineMajor topic
Neoplasm Recurrence, LocalMajor topic
Adult
Aged
Female
Humans
Male
Middle Aged

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
ZIDBC011098NIH

Source NIH RePORTER

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00295815Enzastaurin Versus Lomustine in GlioblastomaResults

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118,981,465Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.J Clin Oncol2008https://conductscience.org/library/papers/18981465PubMed
28,453,582Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.Cancer1993https://conductscience.org/library/papers/8453582PubMed
310,213,484Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis.Cancer Res1999https://conductscience.org/library/papers/10213484PubMed
412,559,880Primary brain tumours in adults.Lancet2003https://conductscience.org/library/papers/12559880PubMed
516,943,527Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.J Clin Oncol2006https://conductscience.org/library/papers/16943527PubMed
614,638,850Phase II trial of gefitinib in recurrent glioblastoma.J Clin Oncol2004https://conductscience.org/library/papers/14638850PubMed
714,745,879Temozolomide in the treatment of recurrent malignant glioma.Cancer2004https://conductscience.org/library/papers/14745879PubMed
812,684,411Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.Clin Cancer Res2003https://conductscience.org/library/papers/12684411PubMed
917,212,356Synergistic antiglioma activity of radiotherapy and enzastaurin.Ann Neurol2007https://conductscience.org/library/papers/17212356PubMed
1017,664,483Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.J Clin Oncol2007https://conductscience.org/library/papers/17664483PubMed

1 to 10 of 38

See all 38 references

Cited by258

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 406 citations.

PMIDTitleJournalYearIn PapersSource
42,694,176Comparative efficacy of therapeutic strategies for recurrent or refractory glioblastoma: a systematic review and network meta-analysis.Front Neurol2026https://conductscience.org/library/papers/42694176PubMed
42,548,479Modern brachytherapy in glioblastoma: overcoming clinical barriers to improve local control.Front Oncol2026https://conductscience.org/library/papers/42548479PubMed
42,058,764A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma.Neurooncol Adv2026https://conductscience.org/library/papers/42058764PubMed
41,972,682The Elusive Origin of Glioblastoma: Where Do We Stand?Cells2026https://conductscience.org/library/papers/41972682PubMed
41,683,621Redundancy in Growth Factor Receptor Signaling in Adult Astrocytoma Resistance to Small-Molecule Tyrosine Kinase Inhibitors.Int J Mol Sci2026https://conductscience.org/library/papers/41683621PubMed
41,492,853Unraveling the Molecular Mechanisms of Glioma Recurrence: A Study Integrating Single-Cell and Spatial Transcriptomics.Ann Clin Transl Neurol2026https://conductscience.org/library/papers/41492853PubMed
41,149,461Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma.Curr Oncol2025https://conductscience.org/library/papers/41149461PubMed
41,050,932Current evidence and challenges of multitarget anti-angiogenic agents for glioblastoma: Results from clinical trials.iScience2025https://conductscience.org/library/papers/41050932PubMed
41,007,824Transcriptomic Profile of Isocitrate Dehydrogenase Mutant Type of Lower-Grade Glioma Reveals Molecular Changes for Prognosis.Biomedicines2025https://conductscience.org/library/papers/41007824PubMed
40,827,022Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.Neuro Oncol2025https://conductscience.org/library/papers/40827022PubMed

1 to 10 of 258

See all 258 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
ENZASTAURINCHEMBL300138Results1https://conductscience.org/library/drugs/CHEMBL300138ChEMBL
LOMUSTINECHEMBL514Results1https://conductscience.org/library/drugs/CHEMBL514ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20124186

GET https://conductscience.org/api/papers/v1/20124186/references?page=2

API referenceFor AI assistants